Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Nausea and Vomitting Associated With Stem Cell Transplant: Results of a Prospective, Randomized Trial of Aprepitant Used With Highly Emetogenic Preparative Regimens
Brief Summary: The purpose of this study is to compare two different treatment protocols for treating nausea and vomiting in patients who have undergone bone marrow transplant. Patients will be assigned to one of two treatment groups.

The first group will recieve ondansetron (Zofran) tablets combined with a medicine called dexamethasone given IV. Both of these drugs are commercially available.

Patients in the second treatment consists of the first two drugs, plus a newly approved drug known as aprepitant (MK-869, Emend). This combination will be the treatment being tested. The combination is approved by the FDA for chemotherapy regimens known to cause a lot of nausea and vomiting. It significantly decreases the delayed (more than 24 hours after therapy) nausea and vomiting seen with these regimens.


Options:
A: Arm Label: Aprepitant (MK-0869); Type: EXPERIMENTAL; Interventions: Drug: aprepitant, Drug: granisetron, Drug: dexamethasone | Arm Label: Standard Therapy; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo to aprepitant, Drug: dexamethasone, Drug: granisetron | Intervention Type: DRUG; Name: aprepitant; Assigned to Arm(s): Aprepitant (MK-0869) | Intervention Type: DRUG; Name: Comparator: Placebo to aprepitant; Assigned to Arm(s): Standard Therapy | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): Standard Therapy | Intervention Type: DRUG; Name: granisetron; Assigned to Arm(s): Aprepitant (MK-0869), Standard Therapy | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): Aprepitant (MK-0869)
B: Arm Label: Netupitant and Palonosetron plus dexamethasone; Type: EXPERIMENTAL; Interventions: Drug: Netupitant and Palonosetron, Drug: Dexamethasone | Arm Label: Aprepitant and Palonosetron plus dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aprepitant, Drug: Palonosetron, Drug: Dexamethasone | Intervention Type: DRUG; Name: Netupitant and Palonosetron; Assigned to Arm(s): Netupitant and Palonosetron plus dexamethasone | Intervention Type: DRUG; Name: Aprepitant; Assigned to Arm(s): Aprepitant and Palonosetron plus dexamethasone | Intervention Type: DRUG; Name: Palonosetron; Assigned to Arm(s): Aprepitant and Palonosetron plus dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Aprepitant and Palonosetron plus dexamethasone, Netupitant and Palonosetron plus dexamethasone
C: Arm Label: Standard PO (Zofran + Dexamethasone); Type: PLACEBO_COMPARATOR; Interventions: Drug: Standard PO (Zofran + Dexamethason) | Arm Label: Aprepitant (MK-869) + Standard PO; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aprepitant (MK-869) + Standard PO | Intervention Type: DRUG; Name: Standard PO (Zofran + Dexamethason); Assigned to Arm(s): Standard PO (Zofran + Dexamethasone) | Intervention Type: DRUG; Name: Aprepitant (MK-869) + Standard PO; Assigned to Arm(s): Aprepitant (MK-869) + Standard PO
D: Intervention Type: DRUG; Name: ONO-7436; Assigned to Arm(s): N/A

Answer: C